Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells

Amy L. Strong, Quan Jiang, Qiang Zhang, Shilong Zheng, Stephen M. Boue, Steven Elliott, Matthew E. Burow, Bruce A. Bunnell, Guangdi Wang

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Osteoporosis is caused by an overstimulation of osteoclast activity and the destruction of the bone extracellular matrix. Without the normal architecture, osteoblast cells are unable to rebuild phenotypically normal bone. Hormone replacement therapy with estrogen has been effective in increasing osteoblast activity but also has resulted in the increased incidence of breast and uterine cancer. In this study we designed and synthesized a series of daidzein analogs to investigate their osteogenic induction potentials. Human bone marrow derived mesenchymal stem cells (MSCs) from three different donors were treated with daidzein analogs and demonstrated enhanced osteogenesis when compared to daidzein treatment. The enhanced osteogenic potential of these daidzein analogs resulted in increased osterix (Sp7), alkaline phosphatase (ALP), osteopontin (OPN), and insulin-like growth factor 1 (IGF-1), which are osteogenic transcription factors that regulate the maturation of osteogenic progenitor cells into mature osteoblast cells.

Original languageEnglish
Pages (from-to)143-148
Number of pages6
JournalACS Medicinal Chemistry Letters
Issue number2
StatePublished - 13 Feb 2014


  • BMSCs
  • Daidzein analogs
  • mesenchymal stem cells
  • osteogenesis


Dive into the research topics of 'Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells'. Together they form a unique fingerprint.

Cite this